Global Nasal Drug Delivery Technology Industry

NEW YORK, Oct. 21, 2020 /PRNewswire/ — Amid the COVID-19 crisis, the global market for Nasal Drug Delivery Technology estimated at US$51.6 Billion in the year 2020, is projected to reach a revised size of US$73.3 Billion by 2027, growing at a CAGR of 5.1% over the analysis period 2020-2027. Nasal Sprays, one of the segments analyzed in the report, is projected to record a 6.2% CAGR and reach US$40 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Drops & Liquids segment is readjusted to a revised 4.4% CAGR for the next 7-year period.

Read the full report: https://www.reportlinker.com/p05799205/?utm_source=PRN

The U.S. Market is Estimated at $15.2 Billion, While China is Forecast to Grow at 4.8% CAGR

The Nasal Drug Delivery Technology market in the U.S. is estimated at US$15.2 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$12.9 Billion by the year 2027 trailing a CAGR of 4.8% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5% and 4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.1% CAGR.

Other Dosage Forms Segment to Record 2.5% CAGR

In the global Other Dosage Forms segment, USA, Canada, Japan, China and Europe will drive the 2.5% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$4.2 Billion in the year 2020 will reach a projected size of US$5 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$8.4 Billion by the year 2027.We bring years of research experience to this 7th edition of our report. The 278-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.

Competitors identified in this market include, among others,

  • 3M Company
  • Aegis Therapeutics LLC
  • Aptargroup, Inc.
  • AstraZeneca PLC
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis International AG
  • Pfizer, Inc.

Read the full report: https://www.reportlinker.com/p05799205/?utm_source=PRN

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Global Competitor Market Shares
Nasal Drug Delivery Technology Competitor Market Share Scenario
Worldwide (in %): 2019 & 2025
Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Nasal Drug
Delivery Technology by Geographic Region – USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets –
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027

Table 2: World Historic Review for Nasal Drug Delivery
Technology by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets – Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019

Table 3: World 15-Year Perspective for Nasal Drug Delivery
Technology by Geographic Region – Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets for Years 2012, 2020 & 2027

Table 4: World Current & Future Analysis for Nasal Sprays by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets – Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027

Table 5: World Historic Review for Nasal Sprays by Geographic
Region – USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets – Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019

Table 6: World 15-Year Perspective for Nasal Sprays by
Geographic Region – Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 7: World Current & Future Analysis for Drops & Liquids by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets – Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027

Table 8: World Historic Review for Drops & Liquids by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets – Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019

Table 9: World 15-Year Perspective for Drops & Liquids by
Geographic Region – Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 10: World Current & Future Analysis for Other Dosage
Forms by Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets – Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027

Table 11: World Historic Review for Other Dosage Forms by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets – Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019

Table 12: World 15-Year Perspective for Other Dosage Forms by
Geographic Region – Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 13: World Current & Future Analysis for Multi-dose by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets – Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027

Table 14: World Historic Review for Multi-dose by Geographic
Region – USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets – Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019

Table 15: World 15-Year Perspective for Multi-dose by
Geographic Region – Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 16: World Current & Future Analysis for Unit-dose by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets – Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027

Table 17: World Historic Review for Unit-dose by Geographic
Region – USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets – Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019

Table 18: World 15-Year Perspective for Unit-dose by Geographic
Region – Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2012, 2020 & 2027

Table 19: World Current & Future Analysis for Bi-dose by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets – Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027

Table 20: World Historic Review for Bi-dose by Geographic
Region – USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets – Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019

Table 21: World 15-Year Perspective for Bi-dose by Geographic
Region – Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2012, 2020 & 2027

Table 22: World Current & Future Analysis for Allergic &
Non-allergic Rhinitis by Geographic Region – USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World Markets –
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027

Table 23: World Historic Review for Allergic & Non-allergic
Rhinitis by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets – Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019

Table 24: World 15-Year Perspective for Allergic & Non-allergic
Rhinitis by Geographic Region – Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World for Years 2012, 2020 & 2027

Table 25: World Current & Future Analysis for Nose Congestion
by Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets – Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027

Table 26: World Historic Review for Nose Congestion by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets – Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019

Table 27: World 15-Year Perspective for Nose Congestion by
Geographic Region – Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 28: World Current & Future Analysis for Vaccination by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets – Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027

Table 29: World Historic Review for Vaccination by Geographic
Region – USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets – Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019

Table 30: World 15-Year Perspective for Vaccination by
Geographic Region – Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 31: World Current & Future Analysis for Other Therapeutic
Applications by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets – Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027

Table 32: World Historic Review for Other Therapeutic
Applications by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets – Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019

Table 33: World 15-Year Perspective for Other Therapeutic
Applications by Geographic Region – Percentage Breakdown of
Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific
and Rest of World for Years 2012, 2020 & 2027

Table 34: World Current & Future Analysis for Home Care
Settings by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets – Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027

Table 35: World Historic Review for Home Care Settings by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets – Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019

Table 36: World 15-Year Perspective for Home Care Settings by
Geographic Region – Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 37: World Current & Future Analysis for Hospitals by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets – Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027

Table 38: World Historic Review for Hospitals by Geographic
Region – USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets – Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019

Table 39: World 15-Year Perspective for Hospitals by Geographic
Region – Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2012, 2020 & 2027

III. MARKET ANALYSIS

GEOGRAPHIC MARKET ANALYSIS

UNITED STATES
Market Facts & Figures
US Nasal Drug Delivery Technology Market Share (in %) by
Company: 2019 & 2025
Market Analytics
Table 40: USA Current & Future Analysis for Nasal Drug Delivery
Technology by Dosage Form – Nasal Sprays, Drops & Liquids and
Other Dosage Forms – Independent Analysis of Annual Sales in
US$ Million for the Years 2020 through 2027

Table 41: USA Historic Review for Nasal Drug Delivery
Technology by Dosage Form – Nasal Sprays, Drops & Liquids and
Other Dosage Forms Markets – Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019

Table 42: USA 15-Year Perspective for Nasal Drug Delivery
Technology by Dosage Form – Percentage Breakdown of Value Sales
for Nasal Sprays, Drops & Liquids and Other Dosage Forms for
the Years 2012, 2020 & 2027

Table 43: USA Current & Future Analysis for Nasal Drug Delivery
Technology by System – Multi-dose, Unit-dose and Bi-dose –
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027

Table 44: USA Historic Review for Nasal Drug Delivery
Technology by System – Multi-dose, Unit-dose and Bi-dose
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019

Table 45: USA 15-Year Perspective for Nasal Drug Delivery
Technology by System – Percentage Breakdown of Value Sales for
Multi-dose, Unit-dose and Bi-dose for the Years 2012, 2020 &
2027

Table 46: USA Current & Future Analysis for Nasal Drug Delivery
Technology by Therapeutic Application – Allergic & Non-allergic
Rhinitis, Nose Congestion, Vaccination and Other Therapeutic
Applications – Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027

Table 47: USA Historic Review for Nasal Drug Delivery
Technology by Therapeutic Application – Allergic & Non-allergic
Rhinitis, Nose Congestion, Vaccination and Other Therapeutic
Applications Markets – Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019

Table 48: USA 15-Year Perspective for Nasal Drug Delivery
Technology by Therapeutic Application – Percentage Breakdown of
Value Sales for Allergic & Non-allergic Rhinitis, Nose
Congestion, Vaccination and Other Therapeutic Applications for
the Years 2012, 2020 & 2027

Table 49: USA Current & Future Analysis for Nasal Drug Delivery
Technology by End-Use – Home Care Settings and Hospitals –
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027

Table 50: USA Historic Review for Nasal Drug Delivery
Technology by End-Use – Home Care Settings and Hospitals
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019

Table 51: USA 15-Year Perspective for Nasal Drug Delivery
Technology by End-Use – Percentage Breakdown of Value Sales for
Home Care Settings and Hospitals for the Years 2012, 2020 &
2027

CANADA
Table 52: Canada Current & Future Analysis for Nasal Drug
Delivery Technology by Dosage Form – Nasal Sprays, Drops &
Liquids and Other Dosage Forms – Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027

Table 53: Canada Historic Review for Nasal Drug Delivery
Technology by Dosage Form – Nasal Sprays, Drops & Liquids and
Other Dosage Forms Markets – Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019

Table 54: Canada 15-Year Perspective for Nasal Drug Delivery
Technology by Dosage Form – Percentage Breakdown of Value Sales
for Nasal Sprays, Drops & Liquids and Other Dosage Forms for
the Years 2012, 2020 & 2027

Table 55: Canada Current & Future Analysis for Nasal Drug
Delivery Technology by System – Multi-dose, Unit-dose and
Bi-dose – Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027

Table 56: Canada Historic Review for Nasal Drug Delivery
Technology by System – Multi-dose, Unit-dose and Bi-dose
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019

Table 57: Canada 15-Year Perspective for Nasal Drug Delivery
Technology by System – Percentage Breakdown of Value Sales for
Multi-dose, Unit-dose and Bi-dose for the Years 2012, 2020 &
2027

Table 58: Canada Current & Future Analysis for Nasal Drug
Delivery Technology by Therapeutic Application – Allergic &
Non-allergic Rhinitis, Nose Congestion, Vaccination and Other
Therapeutic Applications – Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027

Table 59: Canada Historic Review for Nasal Drug Delivery
Technology by Therapeutic Application – Allergic & Non-allergic
Rhinitis, Nose Congestion, Vaccination and Other Therapeutic
Applications Markets – Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019

Table 60: Canada 15-Year Perspective for Nasal Drug Delivery
Technology by Therapeutic Application – Percentage Breakdown of
Value Sales for Allergic & Non-allergic Rhinitis, Nose
Congestion, Vaccination and Other Therapeutic Applications for
the Years 2012, 2020 & 2027

Table 61: Canada Current & Future Analysis for Nasal Drug
Delivery Technology by End-Use – Home Care Settings and
Hospitals – Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027

Table 62: Canada Historic Review for Nasal Drug Delivery
Technology by End-Use – Home Care Settings and Hospitals
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019

Table 63: Canada 15-Year Perspective for Nasal Drug Delivery
Technology by End-Use – Percentage Breakdown of Value Sales for
Home Care Settings and Hospitals for the Years 2012, 2020 &
2027

JAPAN
Table 64: Japan Current & Future Analysis for Nasal Drug
Delivery Technology by Dosage Form – Nasal Sprays, Drops &
Liquids and Other Dosage Forms – Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027

Table 65: Japan Historic Review for Nasal Drug Delivery
Technology by Dosage Form – Nasal Sprays, Drops & Liquids and
Other Dosage Forms Markets – Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019

Table 66: Japan 15-Year Perspective for Nasal Drug Delivery
Technology by Dosage Form – Percentage Breakdown of Value Sales
for Nasal Sprays, Drops & Liquids and Other Dosage Forms for
the Years 2012, 2020 & 2027

Table 67: Japan Current & Future Analysis for Nasal Drug
Delivery Technology by System – Multi-dose, Unit-dose and
Bi-dose – Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027

Table 68: Japan Historic Review for Nasal Drug Delivery
Technology by System – Multi-dose, Unit-dose and Bi-dose
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019

Table 69: Japan 15-Year Perspective for Nasal Drug Delivery
Technology by System – Percentage Breakdown of Value Sales for
Multi-dose, Unit-dose and Bi-dose for the Years 2012, 2020 &
2027

Table 70: Japan Current & Future Analysis for Nasal Drug
Delivery Technology by Therapeutic Application – Allergic &
Non-allergic Rhinitis, Nose Congestion, Vaccination and Other
Therapeutic Applications – Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027

Table 71: Japan Historic Review for Nasal Drug Delivery
Technology by Therapeutic Application – Allergic & Non-allergic
Rhinitis, Nose Congestion, Vaccination and Other Therapeutic
Applications Markets – Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019

Table 72: Japan 15-Year Perspective for Nasal Drug Delivery
Technology by Therapeutic Application – Percentage Breakdown of
Value Sales for Allergic & Non-allergic Rhinitis, Nose
Congestion, Vaccination and Other Therapeutic Applications for
the Years 2012, 2020 & 2027

Table 73: Japan Current & Future Analysis for Nasal Drug
Delivery Technology by End-Use – Home Care Settings and
Hospitals – Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027

Table 74: Japan Historic Review for Nasal Drug Delivery
Technology by End-Use – Home Care Settings and Hospitals
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019

Table 75: Japan 15-Year Perspective for Nasal Drug Delivery
Technology by End-Use – Percentage Breakdown of Value Sales for
Home Care Settings and Hospitals for the Years 2012, 2020 &
2027

CHINA
Table 76: China Current & Future Analysis for Nasal Drug
Delivery Technology by Dosage Form – Nasal Sprays, Drops &
Liquids and Other Dosage Forms – Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027

Table 77: China Historic Review for Nasal Drug Delivery
Technology by Dosage Form – Nasal Sprays, Drops & Liquids and
Other Dosage Forms Markets – Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019

Table 78: China 15-Year Perspective for Nasal Drug Delivery
Technology by Dosage Form – Percentage Breakdown of Value Sales
for Nasal Sprays, Drops & Liquids and Other Dosage Forms for
the Years 2012, 2020 & 2027

Table 79: China Current & Future Analysis for Nasal Drug
Delivery Technology by System – Multi-dose, Unit-dose and
Bi-dose – Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027

Table 80: China Historic Review for Nasal Drug Delivery
Technology by System – Multi-dose, Unit-dose and Bi-dose
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019

Table 81: China 15-Year Perspective for Nasal Drug Delivery
Technology by System – Percentage Breakdown of Value Sales for
Multi-dose, Unit-dose and Bi-dose for the Years 2012, 2020 &
2027

Table 82: China Current & Future Analysis for Nasal Drug
Delivery Technology by Therapeutic Application – Allergic &
Non-allergic Rhinitis, Nose Congestion, Vaccination and Other
Therapeutic Applications – Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027

Table 83: China Historic Review for Nasal Drug Delivery
Technology by Therapeutic Application – Allergic & Non-allergic
Rhinitis, Nose Congestion, Vaccination and Other Therapeutic
Applications Markets – Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019

Table 84: China 15-Year Perspective for Nasal Drug Delivery
Technology by Therapeutic Application – Percentage Breakdown of
Value Sales for Allergic & Non-allergic Rhinitis, Nose
Congestion, Vaccination and Other Therapeutic Applications for
the Years 2012, 2020 & 2027

Table 85: China Current & Future Analysis for Nasal Drug
Delivery Technology by End-Use – Home Care Settings and
Hospitals – Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027

Table 86: China Historic Review for Nasal Drug Delivery
Technology by End-Use – Home Care Settings and Hospitals
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019

Table 87: China 15-Year Perspective for Nasal Drug Delivery
Technology by End-Use – Percentage Breakdown of Value Sales for
Home Care Settings and Hospitals for the Years 2012, 2020 &
2027

EUROPE
Market Facts & Figures
European Nasal Drug Delivery Technology Market: Competitor
Market Share Scenario (in %) for 2019 & 2025
Market Analytics
Table 88: Europe Current & Future Analysis for Nasal Drug
Delivery Technology by Geographic Region – France, Germany,
Italy, UK and Rest of Europe Markets – Independent Analysis of
Annual Sales in US$ Million for Years 2020 through 2027

Table 89: Europe Historic Review for Nasal Drug Delivery
Technology by Geographic Region – France, Germany, Italy, UK
and Rest of Europe Markets – Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019

Table 90: Europe 15-Year Perspective for Nasal Drug Delivery
Technology by Geographic Region – Percentage Breakdown of Value
Sales for France, Germany, Italy, UK and Rest of Europe Markets
for Years 2012, 2020 & 2027

Table 91: Europe Current & Future Analysis for Nasal Drug
Delivery Technology by Dosage Form – Nasal Sprays, Drops &
Liquids and Other Dosage Forms – Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027

Table 92: Europe Historic Review for Nasal Drug Delivery
Technology by Dosage Form – Nasal Sprays, Drops & Liquids and
Other Dosage Forms Markets – Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019

Table 93: Europe 15-Year Perspective for Nasal Drug Delivery
Technology by Dosage Form – Percentage Breakdown of Value Sales
for Nasal Sprays, Drops & Liquids and Other Dosage Forms for
the Years 2012, 2020 & 2027

Table 94: Europe Current & Future Analysis for Nasal Drug
Delivery Technology by System – Multi-dose, Unit-dose and
Bi-dose – Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027

Table 95: Europe Historic Review for Nasal Drug Delivery
Technology by System – Multi-dose, Unit-dose and Bi-dose
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019

Table 96: Europe 15-Year Perspective for Nasal Drug Delivery
Technology by System – Percentage Breakdown of Value Sales for
Multi-dose, Unit-dose and Bi-dose for the Years 2012, 2020 &
2027

Table 97: Europe Current & Future Analysis for Nasal Drug
Delivery Technology by Therapeutic Application – Allergic &
Non-allergic Rhinitis, Nose Congestion, Vaccination and Other
Therapeutic Applications – Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027

Table 98: Europe Historic Review for Nasal Drug Delivery
Technology by Therapeutic Application – Allergic & Non-allergic
Rhinitis, Nose Congestion, Vaccination and Other Therapeutic
Applications Markets – Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019

Table 99: Europe 15-Year Perspective for Nasal Drug Delivery
Technology by Therapeutic Application – Percentage Breakdown of
Value Sales for Allergic & Non-allergic Rhinitis, Nose
Congestion, Vaccination and Other Therapeutic Applications for
the Years 2012, 2020 & 2027

Table 100: Europe Current & Future Analysis for Nasal Drug
Delivery Technology by End-Use – Home Care Settings and
Hospitals – Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027

Table 101: Europe Historic Review for Nasal Drug Delivery
Technology by End-Use – Home Care Settings and Hospitals
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019

Table 102: Europe 15-Year Perspective for Nasal Drug Delivery
Technology by End-Use – Percentage Breakdown of Value Sales for
Home Care Settings and Hospitals for the Years 2012, 2020 &
2027

FRANCE
Table 103: France Current & Future Analysis for Nasal Drug
Delivery Technology by Dosage Form – Nasal Sprays, Drops &
Liquids and Other Dosage Forms – Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027

Table 104: France Historic Review for Nasal Drug Delivery
Technology by Dosage Form – Nasal Sprays, Drops & Liquids and
Other Dosage Forms Markets – Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019

Table 105: France 15-Year Perspective for Nasal Drug Delivery
Technology by Dosage Form – Percentage Breakdown of Value Sales
for Nasal Sprays, Drops & Liquids and Other Dosage Forms for
the Years 2012, 2020 & 2027

Table 106: France Current & Future Analysis for Nasal Drug
Delivery Technology by System – Multi-dose, Unit-dose and
Bi-dose – Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027

Table 107: France Historic Review for Nasal Drug Delivery
Technology by System – Multi-dose, Unit-dose and Bi-dose
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019

Table 108: France 15-Year Perspective for Nasal Drug Delivery
Technology by System – Percentage Breakdown of Value Sales for
Multi-dose, Unit-dose and Bi-dose for the Years 2012, 2020 &
2027

Table 109: France Current & Future Analysis for Nasal Drug
Delivery Technology by Therapeutic Application – Allergic &
Non-allergic Rhinitis, Nose Congestion, Vaccination and Other
Therapeutic Applications – Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027

Table 110: France Historic Review for Nasal Drug Delivery
Technology by Therapeutic Application – Allergic & Non-allergic
Rhinitis, Nose Congestion, Vaccination and Other Therapeutic
Applications Markets – Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019

Table 111: France 15-Year Perspective for Nasal Drug Delivery
Technology by Therapeutic Application – Percentage Breakdown of
Value Sales for Allergic & Non-allergic Rhinitis, Nose
Congestion, Vaccination and Other Therapeutic Applications for
the Years 2012, 2020 & 2027

Table 112: France Current & Future Analysis for Nasal Drug
Delivery Technology by End-Use – Home Care Settings and
Hospitals – Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027

Table 113: France Historic Review for Nasal Drug Delivery
Technology by End-Use – Home Care Settings and Hospitals
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019

Table 114: France 15-Year Perspective for Nasal Drug Delivery
Technology by End-Use – Percentage Breakdown of Value Sales for
Home Care Settings and Hospitals for the Years 2012, 2020 &
2027

GERMANY
Table 115: Germany Current & Future Analysis for Nasal Drug
Delivery Technology by Dosage Form – Nasal Sprays, Drops &
Liquids and Other Dosage Forms – Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027

Table 116: Germany Historic Review for Nasal Drug Delivery
Technology by Dosage Form – Nasal Sprays, Drops & Liquids and
Other Dosage Forms Markets – Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019

Table 117: Germany 15-Year Perspective for Nasal Drug Delivery
Technology by Dosage Form – Percentage Breakdown of Value Sales
for Nasal Sprays, Drops & Liquids and Other Dosage Forms for
the Years 2012, 2020 & 2027

Table 118: Germany Current & Future Analysis for Nasal Drug
Delivery Technology by System – Multi-dose, Unit-dose and
Bi-dose – Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027

Table 119: Germany Historic Review for Nasal Drug Delivery
Technology by System – Multi-dose, Unit-dose and Bi-dose
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019

Table 120: Germany 15-Year Perspective for Nasal Drug Delivery
Technology by System – Percentage Breakdown of Value Sales for
Multi-dose, Unit-dose and Bi-dose for the Years 2012, 2020 &
2027

Table 121: Germany Current & Future Analysis for Nasal Drug
Delivery Technology by Therapeutic Application – Allergic &
Non-allergic Rhinitis, Nose Congestion, Vaccination and Other
Therapeutic Applications – Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027

Table 122: Germany Historic Review for Nasal Drug Delivery
Technology by Therapeutic Application – Allergic & Non-allergic
Rhinitis, Nose Congestion, Vaccination and Other Therapeutic
Applications Markets – Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019

Table 123: Germany 15-Year Perspective for Nasal Drug Delivery
Technology by Therapeutic Application – Percentage Breakdown of
Value Sales for Allergic & Non-allergic Rhinitis, Nose
Congestion, Vaccination and Other Therapeutic Applications for
the Years 2012, 2020 & 2027

Table 124: Germany Current & Future Analysis for Nasal Drug
Delivery Technology by End-Use – Home Care Settings and
Hospitals – Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027

Table 125: Germany Historic Review for Nasal Drug Delivery
Technology by End-Use – Home Care Settings and Hospitals
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019

Table 126: Germany 15-Year Perspective for Nasal Drug Delivery
Technology by End-Use – Percentage Breakdown of Value Sales for
Home Care Settings and Hospitals for the Years 2012, 2020 &
2027

ITALY
Table 127: Italy Current & Future Analysis for Nasal Drug
Delivery Technology by Dosage Form – Nasal Sprays, Drops &
Liquids and Other Dosage Forms – Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027

Table 128: Italy Historic Review for Nasal Drug Delivery
Technology by Dosage Form – Nasal Sprays, Drops & Liquids and
Other Dosage Forms Markets – Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019

Table 129: Italy 15-Year Perspective for Nasal Drug Delivery
Technology by Dosage Form – Percentage Breakdown of Value Sales
for Nasal Sprays, Drops & Liquids and Other Dosage Forms for
the Years 2012, 2020 & 2027

Table 130: Italy Current & Future Analysis for Nasal Drug
Delivery Technology by System – Multi-dose, Unit-dose and
Bi-dose – Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027

Table 131: Italy Historic Review for Nasal Drug Delivery
Technology by System – Multi-dose, Unit-dose and Bi-dose
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019

Table 132: Italy 15-Year Perspective for Nasal Drug Delivery
Technology by System – Percentage Breakdown of Value Sales for
Multi-dose, Unit-dose and Bi-dose for the Years 2012, 2020 &
2027

Table 133: Italy Current & Future Analysis for Nasal Drug
Delivery Technology by Therapeutic Application – Allergic &
Non-allergic Rhinitis, Nose Congestion, Vaccination and Other
Therapeutic Applications – Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027

Table 134: Italy Historic Review for Nasal Drug Delivery
Technology by Therapeutic Application – Allergic & Non-allergic
Rhinitis, Nose Congestion, Vaccination and Other Therapeutic
Applications Markets – Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019

Table 135: Italy 15-Year Perspective for Nasal Drug Delivery

Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p05799205/?utm_source=PRN

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.

__________________________
Contact Clare: [email protected]  
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

Related Links

www.reportlinker.com